Immunosuppressive therapy for patients with myelodysplastic syndrome

• Verfasst von: Passweg, Jakob R. [VerfasserIn]
• Verfasst von: Giagounidis, Aristoteles [VerfasserIn]
• Verfasst von: Simcock, Mathew [VerfasserIn]
• Verfasst von: Aul, Carlo [VerfasserIn]
• Verfasst von: Dobbelstein, Christiane [VerfasserIn]
• Verfasst von: Stadler, Michael [VerfasserIn]
• Verfasst von: Ossenkoppele, Gert [VerfasserIn]
• Verfasst von: Hofmann, Wolf-Karsten [VerfasserIn]
• Verfasst von: Schilling, Kristina [VerfasserIn]
• Verfasst von: Tichelli, André [VerfasserIn]
• Verfasst von: Ganser, Arnold [VerfasserIn]
• Titel: Immunosuppressive therapy for patients with myelodysplastic syndrome
• Titelzusatz: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care—SAKK 33/99
• Verf.angabe: Jakob R. Passweg, Aristoteles A.N. Giagounidis, Mathew Simcock, Carlo Aul, Christiane Dobbelstein, Michael Stadler, Gert Ossenkoppele, Wolf-Karsten Hofmann, Kristina Schilling, André Tichelli, Arnold Ganser
• Jahr: 2011
• Umfang: 7 S.
• Fussnoten: Published online ahead of print on December 13, 2010 ; Gesehen am 22.09.2022
• Titel Quelle: Enthalten in: Journal of clinical oncology
• Ort Quelle: Alexandria, Va. : American Society of Clinical Oncology, 1983
• Jahr Quelle: 2011
• Band/Heft Quelle: 29(2011), 3, Seite 303-309
• ISSN Quelle: 1527-7755
• DOI: doi:10.1200/JCO.2010.31.2686
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adult
• Sach-SW: Aged
• Sach-SW: Antilymphocyte Serum
• Sach-SW: Cell Transformation, Neoplastic
• Sach-SW: Cross-Over Studies
• Sach-SW: Cyclosporine
• Sach-SW: Drug Therapy, Combination
• Sach-SW: Female
• Sach-SW: Health Services
• Sach-SW: Humans
• Sach-SW: Immunosuppressive Agents
• Sach-SW: Intention to Treat Analysis
• Sach-SW: Logistic Models
• Sach-SW: Male
• Sach-SW: Middle Aged
• Sach-SW: Myelodysplastic Syndromes
• Sach-SW: Prospective Studies
• Sach-SW: Survival Analysis
• K10plus-PPN: 1817289659

Abstract

PURPOSE: Immunosuppressive treatment is reported to improve cytopenia in some patients with myelodysplastic syndrome (MDS). Combined antithymocyte globulin (ATG) and cyclosporine (CSA) is most effective in patients with immune-mediated marrow failure. - PATIENTS AND METHODS: This trial was designed to assess the impact of immunosuppression on hematopoiesis, transfusion requirements, transformation, and survival in patients with MDS randomly assigned to 15 mg/kg of horse ATG for 5 days and oral CSA for 180 days (ATG+CSA) or best supportive care (BSC), stratified by treatment center and International Prognostic Scoring System (IPSS) risk score. Primary end point was best hematologic response at 6 months. Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤ 2 and transfusion dependency of less than 2 years in duration. - RESULTS: Between 2000 and 2006, 45 patients received ATG+CSA (median age, 62 years; range, 23 to 75 years; 56% men) and 43 patients received BSC (median age, 65 years; range, 24 to 76 years; 81% men). IPSS score was low, intermediate-1, intermediate-2, high, and not evaluable in eight, 24, seven, one, and five patients on ATG+CSA, respectively, and eight, 25, five, zero, and five patients on BSC, respectively. Refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess of blasts (RAEB) -I, RAEB-II, and hypoplastic disease were present in 21, six, nine, zero, and nine patients on ATG+CSA, respectively, and 18, eight, 11, two, and four patients on BSC, respectively. By month 6, 13 of 45 patients on ATG+CSA had a hematologic response compared with four of 43 patients on BSC (P = .0156). Two-year transformation-free survival (TFS) rates were 46% (95% CI, 28% to 62%) and 55% (95% CI, 34% to 70%) for ATG+CSA and BSC patients, respectively (P = .730), whereas overall survival (OS) estimates were 49% (95% CI, 31% to 66%) and 63% (95% CI, 42% to 78%), respectively (P = .828). - CONCLUSION: This open-label randomized phase III trial demonstrates that ATG+CSA treatment seems to be associated with hematologic response in a subset of patients without apparent impact on TFS and OS.